Nimbus Therapeutics Secures $210 Million Financing Following $6 Billion Takeda Deal to Advance Next-Generation Small Molecule Pipeline

Sep 07, 2023 07:05 CST Updated 07:05

Nimbus Therapeutics

Small Molecule Drug Developer

On September 6, Boston, Nimbus Therapeutics, a clinical-stage biotechnology company that designs and develops breakthrough drugs through its powerful computational drug discovery engine, announced the completion of a $210 million financing to advance its next wave of technology-supported small molecule drugs. This round of financing was led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture.CommonLead Investment, another new investor / a fund focused on U.S. life sciences, along with existing investors Bain Capital Life Sciences, BVF Partners, Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital Management, and SV Health Investors, also participated in the investment.As of now, Nimbus Therapeutics has cumulatively raised over US$632 million in financing.(Nimbus Therapeutics Completes $125 Million Financing, with Bill Gates Following Up)

Jeb Keiper

Jeb Keiper, CEO of Nimbus Therapeutics, said:"We are proud to have built a research and development organization that is a model of excellence in small molecule drug discovery and development. With the support of a top-tier investor base, a robust pipeline, and an unparalleled team, we are embarking on the next chapter of our history, laying the foundation for our enduring success."

Nimbus will continue to develop in patients with solid tumorsHPK1 InhibitorNDI-101150. The new funding will enable multiple preclinical programs to advance into early clinical development, including projects targeting Werner Syndrome helicase (WRN) and an undisclosed autoimmune disease target. Nimbus is also collaborating with Eli Lilly to develop novel targeted therapies that activate AMPK for the treatment of potentially broad metabolic disorders.$496 Million! Lilly and Nimbus Reach Collaboration Agreement on an AMPK Agonist)

Bruce Booth, Partner at Atlas Venture and Chairman & Co-founder of Nimbus Therapeutics, said:"Nimbus Therapeutics' ability to repeatedly design and develop differentiated, clinically validated small molecules is a testament to the strength of its expert team and its unparalleled structure-based drug design platform. We are pleased to see that the strong investor interest in this financing round reflects this sentiment, and the proceeds will advance Nimbus’ portfolio."

In 2022,Takeda Announces Acquisition of Atlas Venture Partner for Up to $6 Billion (Upfront Payment of $4 Billion)Dr. Bruce BoothNimbus Therapeutics’ incubated BIC TYK2 inhibitor NDI-034858 (now TAK-279). For the detailed transaction and development story, refer to this article: (Bruce Booth and Nimbus: Golden Eggs Are Often Found）。

Follow the official account below to see the world!